TENAX THERAPEUTICS, INC.
No SEC Form 4 filings for $TENX in the last 30 days.
See all $TENX insider activity →US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.
U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.
Tenax Therapeutics (TENX) shares fell about 84% pre-open after its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to meet the primary endpoint for pulmonary hypertension due to heart failure with preserved ejection fraction, with a 3.5-meter least-squares mean difference and p-value 0.63. It also missed a key secondary endpoint. The company is evaluating next steps and has $118 million cash runway through mid-2028.
Over the past 7 days, alphai's AI scored 4 news stories mentioning TENX (TENAX THERAPEUTICS, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent TENX coverage spans market movers, technology and corporate actions.
Primary endpoint failure is a strong negative re-rating event for the development-stage biotech.
Clinical failure sharply reduces TNX-103 regulatory prospects and likely drives near-term risk-off positioning in TENX.
The Phase 3 failure sharply worsens TNX-103’s regulatory prospects and increases near-term financing and development risk.
Primary-endpoint miss increases probability of failure for the program and can pressure near-term financing expectations and partner interest.
The 8-K provides a near-term clinical catalyst (LEVEL topline in August) plus updated funding runway, which can shift risk/reward for TENX ahead of trial readouts.
alphai scores every news story that mentions TENX with an AI model for sentiment and relevance, and aggregates insider trades from TENAX THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.
7 min readU.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.
7 min readTenax Therapeutics (TENX) shares fell about 84% pre-open after its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to meet the primary endpoint for pulmonary hypertension due to heart failure with preserved ejection fraction, with a 3.5-meter least-squares mean difference and p-value 0.63. It also missed a key secondary endpoint. The company is evaluating next steps and has $118 million cash runway through mid-2028.
4 min readReuters reports that Tenax Therapeutics’ Phase 3 Level trial did not meet its primary endpoint. The article provides no additional trial results or financial guidance. The outcome may affect investor expectations for the company’s lead program and future development plans.
1 min readTENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d90330dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE N
4 min readTenax Therapeutics (Nasdaq: TENX) said it granted inducement non-qualified stock options on July 1, 2026 to three newly hired non-executive employees under Nasdaq Rule 5635(c)(4). The awards total 160,000 shares at an exercise price equal to the Nasdaq closing price on grant date, with 25% vesting after one year and the rest monthly over 36 months.
2 min readTenax Therapeutics (Nasdaq: TENX) said Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at the ESC Congress 2026 in late-breaking session. The company expects to report topline data in August 2026; enrollment of 230+ patients finished March 2026.
2 min readTenax Therapeutics (Nasdaq: TENX) said Phase 3 LEVEL trial data for TNX-103 (oral levosimendan) in PH-HFpEF will be presented at the ESC Congress 2026 (Aug 28-31) via a late-breaking session on Aug 29. The company expects topline results in August after database lock and statistical analysis; enrollment of 230+ patients was completed in March 2026.
4 min readTENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0000034956 0000034956 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,
4 min readTENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d251626dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “ Amendment ”), is made as of June 29, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, wit
3 min read
